Title:
COMPOSITION FOR PREVENTING OR TREATING LUPUS, COMPRISING RECOMBINANT STABILIZED GALECTIN 9 PROTEIN
Document Type and Number:
WIPO Patent Application WO/2024/049227
Kind Code:
A1
Abstract:
The present invention relates to a composition for preventing or treating lupus or glomerulonephritis, comprising a recombinant stabilized galectin 9 protein. Specifically, it was confirmed that the recombinant stabilized galectin 9 protein of the present invention shows safety in a systemic lupus erythematosus (SLE) animal model, reduces skin lesions, lymphadenopathy, and proteinuria caused by lupus, alleviates lupus nephritis and glomerulonephritis, and shows the effect of reducing the concentration of anti-dsDNA antibodies in plasma. Therefore, the recombinant stabilized galectin 9 protein of the present invention can be effectively used as an active ingredient in a composition for preventing or treating lupus or glomerulonephritis.
Inventors:
SONG DAVID (KR)
Application Number:
PCT/KR2023/012952
Publication Date:
March 07, 2024
Filing Date:
August 31, 2023
Export Citation:
Assignee:
GBIOLOGICS INC (KR)
International Classes:
A61K38/17; A23L33/17; A61P13/12; A61P37/00
Domestic Patent References:
| WO2021096217A1 | 2021-05-20 | |||
| WO2022108243A1 | 2022-05-27 |
Foreign References:
| US20150307574A1 | 2015-10-29 | |||
| CN103623393A | 2014-03-12 |
Other References:
PANDA SANTOSH K., FACCHINETTI VALERIA, VOYNOVA ELISAVETA, HANABUCHI SHINO, KARNELL JODI L., HANNA RICHARD N., KOLBECK ROLAND, SANJ: "Galectin-9 inhibits TLR7-mediated autoimmunity in murine lupus models", JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 5, 1 May 2018 (2018-05-01), pages 1873 - 1887, XP093145556, ISSN: 0021-9738, DOI: 10.1172/JCI97333
Attorney, Agent or Firm:
HANSUNG INTELLECTUAL PROPERTY (KR)
Download PDF: